Exos Asset Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Exos Asset Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,407	Closed	-$8K	–	448
2021 Q3	$8K	Sell	12,407 -93	-0.7%	-$69	﹤0.01%	430
2021 Q2	$11K	Hold	12,500	–	–	0.01%	764
2021 Q1	$8K	Buy	+12,500	New	+$8.81K	0.01%	396

Other funds holding BIOTW

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Exos Asset Management's BIOTW Position: Q4 2021 in Review

Exos Asset Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q4 2021, closing a stake of 12,407 shares — an estimated $8K sold.

Exos Asset Management first reported a position in BIOTW in Q1 2021 and held it in 3 quarters. The position peaked at $11K in Q2 2021. 56 funds tracked by Wall St. Rank hold BIOTW as of Q4 2021.

Exos Asset Management reported no remaining Biotech Acquisition Company Warrant position as of Q4 2021 after selling out during the quarter.
Exos Asset Management sold 12,407 Biotech Acquisition Company Warrant shares in Q4 2021, an estimated $8K.
Exos Asset Management first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 3 quarters.
Exos Asset Management's Biotech Acquisition Company Warrant position peaked at $11K in Q2 2021.
56 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q4 2021.

Based on Exos Asset Management's 13F filing for Q4 2021, filed 14 Mar 2022.